Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
MGM$28.68-0.15(-0.52%)BetMGM Marks 100 Days in Alberta[9:52:11 AM ET]CACI$679.83+5.46(+0.81%)CACI's Good Dogs for Great Americans Reaches $50K Milestone to Fund First Veteran-Service Dog Team CACI International Inc (NYSE: CACI) today announced a milestone for its Good Dogs for Great Americans philanthropy program. Through this partnership...[9:45:00 AM ET]GXLDF$0.200.00(0.00%)Hi-View Resources Inc. to Attend the 52nd Annual New Orleans Investment Conference[9:30:00 AM ET]UBAB$62.000.00(0.00%)United Bancorporation of Alabama, Inc. Announces Third Quarter Results (OTCQX: UBAB) - United Bancorporation of Alabama, Inc. reported net income of $16.0 million for the nine months ended September 30, 2026, compared to ...[9:30:00 AM ET]DNLI$19.11-0.21(-1.09%)Denali Therapeutics Receives 2026 Prix Galien USA Award for AVLAYAH® (tividenofusp alfa-eknm) as Best Biotechnology Product[9:30:00 AM ET]KVHI$7.83+0.05(+0.64%)KVH Industries to Host Third Quarter Conference Call on November 5, 2026[9:22:13 AM ET]ARAI$0.11-0.01(-7.99%)Arrive AI to Report Q3 2026 Results and Host Webcast on November 13[9:19:00 AM ET]TRNO$65.73+0.01(+0.02%)Terreno Realty Corporation Acquires Property in San Carlos, CA for $29.0 Million[9:15:00 AM ET]VIVK$1.07-0.43(-28.67%)Vivakor Announces Proposed Hydrogen Plant and Fueling Station at a Texas International Airport[9:15:00 AM ET]KBLB$0.080.00(0.00%)Why Kraig Labs’ Spider Silk Could Have a Future in Aerospace[9:15:00 AM ET]CWBK$41.05+0.05(+0.12%)CW Bancorp Reports Third Quarter 2026 Financial Results CW Bancorp (OTCQX: CWBK), the parent company ("the Company") of CommerceWest Bank (the "Bank") reported consolidated net income for the third quarter ...[9:15:00 AM ET]NTHI$3.16+0.04(+1.29%)NeOnc’s Ambitious Brain Cancer Plans are Setting the Stage[9:10:00 AM ET]CURLF$8.42-0.17(-1.95%)Curaleaf Celebrates Graduation of Inaugural New York Incubator Program Class, Announces Future Cohorts and Multi-State Expansion Curaleaf Holdings, Inc. (TSX: CURA) (OTCQX: CURLF) ("Curaleaf"), a leading international provider of consumer cannabis products, today announced the...[9:10:00 AM ET]

PPCB · NASDAQ

Propanc Biopharma, Inc.

$1.89 -0.23 (-10.64%)

Company overview

Propanc Biopharma, Inc. is a biopharmaceutical company focused on developing cancer treatments for patients with pancreatic, ovarian and colorectal cancer in Australia. Its lead product is PRP, a formulation in preclinical development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. Propanc Biopharma was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.

Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Market cap
$4.3M
Employees
1
Headquarters
Camberwell, VIC
Website
propanc.com
CEO
James Nathanielsz
Listed
November 12, 2012
P/E
-0.06
Dividend yield
0.00%

Company financials

Revenue
$0.00
Gross profit
$0.00
Operating income
-$18.4M
EBITDA
-$17.7M
Net income
-$18.4M
EPS
-$33.00
Total assets
$14.3M
Total debt
$1.6M
Earnings yield
-1,746.03%

Price chart

-0.011.753.525.297.05
PPCB 1D NASDAQ O2.12H2.21L2.10C2.12+0.01 (+0.24%)Vol6.37K

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
Ticker Type Headline Source Published
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Advances Bioanalytical & Immunogenicity Assay Development for Phase 1b First-In-Human Study in up to 50 Advanced Cancer Patients GlobeNewswire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Advances Clinical Development Preparation for PRP Phase 1b First-In-Human Study in Up to 50 Advanced Cancer Patients GlobeNewswire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Publishes New Data: PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells & Restores Therapeutic Vulnerability GlobeNewswire
PPCBPropanc Biopharma, Inc. Press release CORRECTION -- Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans GlobeNewswire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans GlobeNewswire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma’s Lead Asset PRP Reprograms Chemotherapy-Resistant Pancreatic Cancer Cells GlobeNewswire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Announces Publication of Pilot Study Demonstrating Potent Anti-Tumor Efficacy of PRP Pancreatic Proenzyme Formulation in Pancreatic & Ovarian Cancer GlobeNewswire
PPCBPropanc Biopharma, Inc. Stock news Propanc Biopharma Inc (NASDAQ:PPCB) Sees Significant Increase in Short Interest Defense World
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Reports Data Showing 90% Tumor Growth Inhibition with PRP in Pancreatic Cancer Models, Contrasting Profile with Revolution Medicines' Daraxonrasib GlobeNewsWire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results GlobeNewswire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Highlights Differentiated PRP Pancreatic GlobeNewswire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Positions PRP’s EMT-Reversal Mechanism as GlobeNewswire
PPCBPropanc Biopharma, Inc. Stock news Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 GlobeNewsWire
PPCBPropanc Biopharma, Inc. Stock news Revolution Medicines' Pancreatic Cancer Drug Approval Validates Microcap Propanc Biopharma's Breakthrough Survival Results Benzinga
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Announces Compelling New Preclinical Pancreatic Cancer Data for PRP Showing >90% Tumor Growth Inhibition and >2.5-Fold Survival Benefit GlobeNewsWire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Clears Path for World-First Phase 1b Clinical Study of Breakthrough Cancer Therapy PRP GlobeNewsWire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Highlights Differentiated Proenzyme Therapy PRP as a Potential Therapy of Choice Against RAS-Driven Cancers GlobeNewsWire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Announces Positive Preclinical and Early Translational Data for PRP Showing >90% Tumor Growth Inhibition and Significant Survival Benefit in Pancreatic Ductal Adenocarcinoma Models GlobeNewsWire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Completes First Tranche of $5.0 Million Share Repurchase Program GlobeNewsWire
PPCBPropanc Biopharma, Inc. Press release Propanc Biopharma Publishes Evaluation of Recombinant Trypsinogen & Chymotrypsinogen in Peer Reviewed Journal GlobeNewsWire
See more
FAQ

Questions about Propanc Biopharma, Inc.

What does Propanc Biopharma, Inc. do?
Propanc Biopharma, Inc. is a biopharmaceutical company focused on developing cancer treatments for patients with pancreatic, ovarian and colorectal cancer in Australia. Its lead product is PRP, a formulation in preclinical development designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company has a research collaboration with University of Jaén to commence the POP1 joint drug discovery program. Propanc Biopharma was formerly known as Propanc Health Group Corporation and changed its name to Propanc Biopharma, Inc. in April 2017. The company was incorporated in 2007 and is based in Camberwell, Australia.
What is PPCB's market cap?
Propanc Biopharma, Inc. (PPCB) is a listed stock with a live quote. The latest market cap on this page is $4.3M.
Where is Propanc Biopharma, Inc. headquartered?
Propanc Biopharma, Inc. is headquartered in Camberwell, VIC.
How do I get PPCB news from the API?
Call GET /v1/news?tickers=PPCB. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does PPCB news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for PPCB, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the PPCB price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs